On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

The grand jury that charged former FBI Director James Comey never saw the version of the indictment that interim U.S.

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Amid steep cuts to U.S. foreign assistance, the Trump administration is touting a new plan to provide a powerful HIV ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...